The relationship between testosterone therapy and prostate cancer continues to challenge historic and current beliefs. A new cohort analysis revealed a ~33% reduction in prostate cancer incidence in men with increased testosterone use. The mechanisms underlying this protective effect are unclear, but these findings challenge current paradigms and warrant further investigation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stavropouls, K. et al. Testosterone replacement therapy and cardiovascular risk - a closer look at additional parameters. JAMA Intern Med. 117, 1393 (2017).
Lopez, D. S. et al. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database. Clin. Endocrinol. https://doi.org/10.1111/cen.14093 (2019).
Loeb, S. et al. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J. Clin. Oncol. 35, 1430–1436 (2017).
Isbarn, H. et al. Testosterone and prostate cancer: revisiting old paradigms. Eur. Urol. 56, 48–56 (2009).
Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate vancer. N. Engl. J. Med. 380, 1235–1246 (2019).
Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170–183 (2008).
Pastuszak, A. W. et al. Testosterone therapy and prostate cancer. Transl Androl. Urol. 5, 909–920 (2016).
Ahlering, T. E. et al. Is there a role for testosterone replacement in reducing biochemical recurrence following radical prostatectomy? J. Clin. Oncol. 37, 5085–5085 (2019).
Kasper, J. S., Liu, Y. & Giovannucci, E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int. J. Cancer 124, 1398–1403 (2009).
Lee, J. et al. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus 5, 1548 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Huynh, L.M., Ahlering, T.E. Challenging beliefs of testosterone therapy and prostate cancer. Nat Rev Urol 16, 699–701 (2019). https://doi.org/10.1038/s41585-019-0253-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0253-8